Publication Name	World Journal of Gastroenterology
Manuscript ID	4594
Country	Portugal

Received	2013-07-09 08:51
Peer-Review Started	2013-07-09 09:36
First Decision by Editorial Office Director
Return for Revision	2013-07-19 09:45
Revised	2013-07-24 06:01
Publication Fee Transferred
Second Decision by Editor	2013-08-06 16:48
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-08-06 23:19
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-28 20:13
Publish the Manuscript Online	2013-10-15 17:26

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies
Manuscript Source	Invited Manuscript
All Author List	Michael Luis, Ana Tavares, Liliana S Carvalho, Lúcio Lara-Santos, António Araújo and Ramon Andrade de Mello
Funding Agency and Grant Number
Corresponding Author	Ramon Andrade de Mello, MD, PhD, Professor, Gastrointestinal Unit, Service of Medical Oncology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ramondemello@gmail.com
Key Words	Gastric cancer; Human epidermal growth factor receptor 2; Biomarkers; Target therapies; Trastuzumab; Lapatinib; Pertuzumab; Trastuzumab-DM1; Afatinib
Core Tip	Advanced gastric cancer is a very aggressive disease thought the standard chemotherapy protocols available. In 2010, Trastuzumab for Gastric Cancer trial showed that the combination of trastuzumab, could be considered a new standard option for patients with human epidermal growth factor receptor 2 (HER2) positive advanced gastric and gastro-esophageal junction cancer. Thus, a new era emerged for those patients due to the interesting possibility in prolong survival in a personalized setting (HER2 positive). Our manuscript will provide an overview of the molecular mechanisms involved and also promising targeted therapies in this field.
Publish Date	2013-10-15 17:26
Citation	Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013; 19(38): 6383-6397
URL	http://www.wjgnet.com/1007-9327/full/v19/i38/6383.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i38.6383

Full Article (PDF)	WJG-19-6383.pdf
Manuscript File	4594-Review.doc
Answering Reviewers	4594-Answering reviewers.pdf
Copyright License Agreement	4594-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4594-Language certificate.pdf
Peer-review Report	4594-Peer review.pdf
Scientific Editor Work List	4594-Scientific editor work list.doc